GT Biopharma (GTBP) Share-based Compensation (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Share-based Compensation of $46000.0 for Q1 2026, up 1433.33% year-over-year from $3000.0 in Q1 2025, and little changed quarter-over-quarter from $46000.0 in Q4 2025.
GT Biopharma (GTBP) Share-based Compensation (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Share-based Compensation for 16 consecutive years, with $46000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 1433.33% year-over-year to $46000.0; the TTM figure through Mar 2026 stood at $475000.0 (up 262.6% YoY), while the FY2025 annual figure was $432000.0, up 87.83% from the prior year.
- Share-based Compensation steadied at $46000.0 in Q1 2026 per GTBP's latest filing, from $46000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $379000.0 in Q3 2025 and bottomed at $2000.0 in Q4 2023.
- Historically, Share-based Compensation has averaged $117500.0 across 4 years, with a median of $74000.0 in 2024.
- Annual changes were most pronounced in 2025 — Share-based Compensation plunged 97.06% — and 2026, when it jumped 1433.33%.
- GT Biopharma's Share-based Compensation stood at $2000.0 in 2023, then jumped by 300.0% to $8000.0 in 2024, then soared by 475.0% to $46000.0 in 2025, then changed by 0.0% to $46000.0 in 2026.
- Business Quant data shows GTBP's Share-based Compensation at $46000.0 in Q1 2026, $46000.0 in Q4 2025, and $379000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - | 46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46,000.00 |
| Mar 31, 2026 | 46,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | 379,000.00 |
| Sep 30, 2025 | 379,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Jun 30, 2024 | 120,000.00 |
| Jun 30, 2024 | 120,000.00 |
| Mar 31, 2024 | 102,000.00 |
| Mar 31, 2024 | 102,000.00 |
| Dec 31, 2023 | 2,000.00 |
| Dec 31, 2023 | 2,000.00 |
| Sep 30, 2023 | 109,000.00 |
| Sep 30, 2023 | 109,000.00 |